Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL648441 | 0.85 | MAPT (0.39) | MAPTPOLBTDP1ALDH1A1NPSR1 | |
| SCHEMBL12087702 | 0.82 | MAPT (0.33) | MAPTPOLBTDP1ALDH1A1NPSR1 | |
| SCHEMBL30596885 | 0.80 | MAPT (0.37) | MAPTPOLBTDP1ALDH1A1NPSR1 | |
| SCHEMBL29300080 | 0.80 | ALDH1A1 (0.39) | MAPTPOLBTDP1ALDH1A1NPSR1 | |
| SCHEMBL30596886 | 0.80 | MAPT (0.37) | MAPTPOLBTDP1ALDH1A1NPSR1 | |
| SCHEMBL31189743 | 0.80 | — | — | |
| SCHEMBL9274316 | 0.80 | HTT (0.33) | — | |
| SCHEMBL2857817 | 0.79 | MAPT (0.35) | MAPTPOLBTDP1ALDH1A1NPSR1 | |
| SCHEMBL7155183 | 0.78 | MAPT (0.36) | MAPTPOLBTDP1ALDH1A1NPSR1 | |
| SCHEMBL11897944 | 0.78 | MAPT (0.36) | MAPTPOLBTDP1ALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015051131-A1 | METHODS FOR PREPARATION OF FLUORINATED ETHERS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2015-04-09 | — | — | WO | claimed |
| WO-2023078059-A1 | ELECTROLYTE, ELECTROCHEMICAL APPARATUS USING SAME, AND ELECTRONIC APPARATUS | 宁德新能源科技有限公司 | 2023-05-11 | — | — | WO | disclosed |
| CN-111886740-A | Lithium ion secondary battery | 日本电气株式会社 | 2020-11-03 | — | — | CN | disclosed |
| CN-111418105-A | Lithium ion secondary battery | 日本电气株式会社 | 2020-07-14 | — | — | CN | disclosed |
| CN-110720156-A | Lithium ion secondary battery | 日本电气株式会社 | 2020-01-21 | — | — | CN | disclosed |
| CN-110637388-A | Electrolyte for lithium ion secondary battery and lithium ion secondary battery using same | 日本电气株式会社 | 2019-12-31 | — | — | CN | disclosed |
| CN-110637389-A | Lithium ion secondary battery | 日本电气株式会社 | 2019-12-31 | — | — | CN | disclosed |
| US-9780409-B2 | Nonaqueous electrolytic solution and nonaqueous-electrolyte battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2017-10-03 | — | — | US | disclosed |
| WO-2015051131-A1 | METHODS FOR PREPARATION OF FLUORINATED ETHERS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2015-04-09 | — | — | WO | disclosed |
| US-20150024284-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS-ELECTROLYTE BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2015-01-22 | — | — | US | disclosed |
| US-20130244122-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS-ELECTROLYTE BATTERY EMPLOYING THE SAME | ONUKI MASAMICHI (JP) | 2013-09-19 | — | — | US | disclosed |
| US-20120219866-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS-ELECTROLYTE BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-08-30 | — | — | US | disclosed |
| EP-2475041-A1 | NON-AQUEOUS ELECTROLYTIC SOLUTION, AND NON-AQUEOUS ELECTROLYTE BATTERY COMPRISING SAME | Mitsubishi Chemical Corporation (JP) | 2012-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150024284-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS-ELECTROLYTE BATTERY EMPLOYING THE SAME | TREH, SLC6A12, SCNN1G | MAPT 3988/4885POLB 328/4885TDP1 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.